Analysts Anticipate ADMA Biologics Inc (ADMA) Will Post Quarterly Sales of $5.56 Million

Equities analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to announce sales of $5.56 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for ADMA Biologics’ earnings, with the highest sales estimate coming in at $6.00 million and the lowest estimate coming in at $4.70 million. ADMA Biologics reported sales of $12.00 million during the same quarter last year, which suggests a negative year over year growth rate of 53.7%. The company is expected to issue its next earnings results on Monday, March 4th.

According to Zacks, analysts expect that ADMA Biologics will report full-year sales of $18.38 million for the current financial year, with estimates ranging from $17.70 million to $18.90 million. For the next financial year, analysts anticipate that the business will post sales of $44.40 million, with estimates ranging from $19.90 million to $94.20 million. Zacks’ sales calculations are an average based on a survey of research firms that follow ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.02). The firm had revenue of $4.23 million during the quarter, compared to the consensus estimate of $5.39 million. ADMA Biologics had a negative net margin of 243.42% and a negative return on equity of 155.19%.

Several equities research analysts recently commented on ADMA shares. Oppenheimer set a $13.00 price target on ADMA Biologics and gave the company a “buy” rating in a research note on Wednesday, October 17th. Maxim Group reissued a “buy” rating and issued a $12.00 price target on shares of ADMA Biologics in a research note on Wednesday, October 17th. Raymond James reissued a “buy” rating and issued a $10.00 price target (down previously from $11.00) on shares of ADMA Biologics in a research note on Friday, October 12th. Finally, HC Wainwright set a $17.00 price target on ADMA Biologics and gave the company a “buy” rating in a research note on Friday, November 9th. Six research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $11.58.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of ADMA Biologics by 2,295.0% during the second quarter. BlackRock Inc. now owns 970,839 shares of the biotechnology company’s stock worth $4,378,000 after buying an additional 930,303 shares during the last quarter. 683 Capital Management LLC lifted its holdings in shares of ADMA Biologics by 9.9% during the second quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock worth $3,991,000 after buying an additional 80,000 shares during the last quarter. AMP Capital Investors Ltd acquired a new position in shares of ADMA Biologics during the second quarter worth approximately $109,000. Renaissance Technologies LLC acquired a new position in shares of ADMA Biologics during the second quarter worth approximately $132,000. Finally, Ardsley Advisory Partners acquired a new position in shares of ADMA Biologics during the second quarter worth approximately $361,000. Institutional investors own 57.49% of the company’s stock.

Shares of NASDAQ ADMA opened at $3.39 on Friday. The company has a market capitalization of $136.74 million, a P/E ratio of -1.77 and a beta of 2.84. ADMA Biologics has a 52 week low of $2.08 and a 52 week high of $6.96. The company has a debt-to-equity ratio of 1.11, a current ratio of 6.32 and a quick ratio of 4.92.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: What are the advantages of the Stochastic Momentum Index?

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply